SEC Form 4 · accession 0000899243-18-026783
EyePoint, Inc. · EYPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nancy Lurker
Officer — President & CEO · Director
Period of report
Oct 12, 2018
Accepted (ET)
Oct 16, 2018 · 4:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001314102
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 12, 2018 | A | 76,667 | $0.00 | A | 211,700 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On October 12, 2018 (the "FDA Approval Date"), the U.S. Food and Drug Administration approved EyePoint Pharmaceutical Inc.'s (the "Company") new drug application for YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. As a result, 38,334 shares representing a previously granted performance stock unit award vested on that date. An additional 38,333 shares from this award will vest on the first anniversary of the FDA Approval Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.